Immunomodulation by the estrogen metabolite 2-methoxyestradiol

Clinical Immunology

Volumn 153, Issue 1, 2014, Pages 40-48

  Stubelius, Alexandra ^a   Erlandsson, Malin C ^a   Islander, Ulrika ^a   Carlsten, Hans ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

17 Estradiol; 2 Methoxyestradiol; Estrogen response elements; Immune regulation; Immune system; Uterus proliferation

Indexed keywords

2 METHOXYESTRADIOL; CD19 ANTIBODY; CD27 ANTIGEN; CD3 ANTIGEN; ESTRADIOL; ESTRADIOL BENZOATE; ESTROGEN; ESTROGEN RECEPTOR; INTERLEUKIN 2 RECEPTOR BETA; LACTATE DEHYDROGENASE; LUCIFERASE; NATURAL KILLER CELL RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; BONE MARROW; CELL SUSPENSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DOSE RESPONSE; DOWN REGULATION; DRUG IMPLANT; DRUG MEGADOSE; DRUG PELLET; ESTROGEN RESPONSIVE ELEMENT; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOPHENOTYPING; INVOLUTION; LIVER; LIVER WEIGHT; LONG TERM CARE; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; SHAM PROCEDURE; SLOW RELEASE FORMULATION; SPLEEN; T LYMPHOCYTE; THYMUS ATROPHY; TREATMENT DURATION; UTERUS GROWTH; UTERUS WEIGHT; WEIGHT GAIN;

17Β-ESTRADIOL; 2-METHOXYESTRADIOL; ESTROGEN RESPONSE ELEMENTS; IMMUNE REGULATION; IMMUNE SYSTEM; UTERUS PROLIFERATION;

ANIMALS; B-LYMPHOCYTES; ESTRADIOL; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; IMMUNOMODULATION; KILLER CELLS, NATURAL; MICE; RECEPTORS, ESTROGEN; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS;

EID: 84899139686     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.03.011     Document Type: Article

References (39)

1. Bruce J.Y., et al. A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Investig. New Drugs 2012, 30(2):794-802.
2. Harrison M.R., et al. A phase II study of 2-methoxyestradiol (2ME2) nanocrystal(R) dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Investig. New Drugs 2011, 29(6):1465-1474.
3. Kulke M.H., et al. A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother. Pharmacol. 2011, 68(2):293-300.
4. Matei D., et al. Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecol. Oncol. 2009, 115(1):90-96.
5. Mabjeesh N.J., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003, 3(4):363-375.
6. Brahn E., et al. An angiogenesis inhibitor, 2-methoxyestradiol, involutes rat collagen-induced arthritis and suppresses gene expression of synovial vascular endothelial growth factor and basic fibroblast growth factor. J. Rheumatol. 2008, 35(11):2119-2128.
7. Stubelius A., et al. Role of 2-methoxyestradiol as inhibitor of arthritis and osteoporosis in a model of postmenopausal rheumatoid arthritis. Clin. Immunol. 2011, 140(1):37-46.
8. Duncan G.S., et al. 2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(51):21034-21039.
9. Erlandsson M.C., et al. Oestrogen receptor specificity in oestradiol-mediated effects on B lymphopoiesis and immunoglobulin production in male mice. Immunology 2003, 108(3):346-351.
10. Hanna N., Schneider M. Enhancement of tumor metastasis and suppression of natural killer cell activity by beta-estradiol treatment. J. Immunol. 1983, 130(2):974-980.
11. Nilsson N., Carlsten H. Estrogen induces suppression of natural killer cell cytotoxicity and augmentation of polyclonal B-cell activation. Cell. Immunol. 1994, 158(1):131-139.
12. Marotti T., et al. In vivo effect of progesteron and estrogen on thymus mass and T-cell functions in female mice. Horm. Metab. Res. 1984, 16(4):201-203.
13. Islander U., et al. Estrogens in rheumatoid arthritis; the immune system and bone. Mol. Cell. Endocrinol. 2011, 335(1):14-29.
14. Straub R.H. The complex role of estrogens in inflammation. Endocr. Rev. 2007, 28(5):521-574.
15. Sibonga J.D., et al. Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat. Endocrinology 2003, 144(3):785-792.
16. Kanasaki K., et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with preeclampsia. Nature 2008, 453(7198):1117-1121.
17. Perez-Sepulveda A., et al. Low 2-methoxyestradiol levels at the first trimester of pregnancy are associated with the development of preeclampsia. Prenat. Diagn. 2012, 32(11):1053-1058.
18. Jobe S.O., Tyler C.T., Magness R.R. Aberrant synthesis, metabolism, and plasma accumulation of circulating estrogens and estrogen metabolites in preeclampsia implications for vascular dysfunction. Hypertension 2013, 61(2):480-487.
19. Stubelius A., et al. Sexual dimorphisms in the immune system of catechol-O-methyltransferase knockout mice. Immunobiology 2012, 217(8):751-760.
20. LaVallee T.M., et al. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res. 2002, 62(13):3691-3697.
21. Sutherland T.E., et al. 2-Methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer. Clin. Cancer Res. 2005, 11(5):1722-1732.
22. Josefsson E., Tarkowski A. Suppression of type II collagen-induced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol. Arthritis Rheum. 1997, 40(1):154-163.
23. Lindberg M.K., et al. Estrogen receptor specificity for the effects of estrogen in ovariectomized mice. J. Endocrinol. 2002, 174(2):167-178.
24. Lemmen J.G., et al. Tissue- and time-dependent estrogen receptor activation in estrogen reporter mice. J. Mol. Endocrinol. 2004, 32(3):689-701.
25. Bourghardt J., et al. The endogenous estradiol metabolite 2-methoxyestradiol reduces atherosclerotic lesion formation in female apolipoprotein E-deficient mice. Endocrinology 2007, 148(9):4128-4132.
26. Hayakawa Y., Smyth M.J. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J. Immunol. 2006, 176(3):1517-1524.
27. Sun J.C., Beilke J.N., Lanier L.L. Adaptive immune features of natural killer cells. Nature 2009, 457(7229):557-561.
28. Brzozowski A.M., et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997, 389(6652):753-758.
29. Wu Y.L., et al. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol. Cell 2005, 18(4):413-424.
30. Schmidt M., et al. Estrone/17beta-estradiol conversion to, and tumor necrosis factor inhibition by, estrogen metabolites in synovial cells of patients with rheumatoid arthritis and patients with osteoarthritis. Arthritis Rheum. 2009, 60(10):2913-2922.
31. Tofovic S.P., et al. Estradiol metabolites attenuate renal and cardiovascular injury induced by chronic nitric oxide synthase inhibition. J. Cardiovasc. Pharmacol. 2005, 46(1):25-35.
32. Kohen P., et al. 2-Methoxyestradiol in the human corpus luteum throughout the luteal phase and its influence on lutein cell steroidogenesis and angiogenic activity. Fertil. Steril. 2013, 100(5):1397-1404. (e1).
33. Rossouw J.E., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288(3):321-333.
34. Riggs B.L., Hartmann L.C. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N. Engl. J. Med. 2003, 348(7):618-629.
35. Erlandsson M.C., et al. Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. J. Endocrinol. 2002, 175(2):319-327.
36. Ireson C.R., et al. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br. J. Cancer 2004, 90(4):932-937.
37. Crooke P.S., et al. Estrogens, enzyme variants, and breast cancer: a risk model. Cancer Epidemiol. Biomarkers Prev. 2006, 15(9):1620-1629.
38. Dawling S., Roodi N., Parl F.F. Methoxyestrogens exert feedback inhibition on cytochrome P450 1A1 and 1B1. Cancer Res. 2003, 63(12):3127-3132.
39. Zhu B.T., et al. Metabolic deglucuronidation and demethylation of estrogen conjugates as a source of parent estrogens and catecholestrogen metabolites in Syrian hamster kidney, a target organ of estrogen-induced tumorigenesis. Toxicol. Appl. Pharmacol. 1996, 136(1):186-193.